STAT+: Pharmalittle: Will widening access to a Covid pill cause resistance? Monkeypox vaccine maker doesn’t see ‘panic’
And so, another working week will soon draw to a close. This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is reasonably modest. We hope to spend time with our short person, catch up on our reading, and maybe watch a moving picture or two. And, of course, we must manicure the Pharmalot grounds. But what about you? The great outdoors are beckoning, so perhaps this is an opportunity to lace up the hiking boots, take your official mascot for a constitutional, or paddle a boat somewhere. You could make time to catch up with a special someone or scavenge the stores and stock up on goods before prices rise still more. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you on Tuesday, since this is a holiday weekend on this side of the pond. …
The White House announced more steps to make the Pfizer antiviral pill, called Paxlovid, more accessible across the U.S. as it projects Covid-19 infections will continue to spread over the summer travel season, the Associated Press reports. The nation’s first federally backed test-to-treat site is opening Thursday in Rhode Island and the U.S. will send authorized federal prescribers to several Minnesota-run testing sites, turning them into test-to-treat locations. Federal regulators have also sent clearer guidance to physicians to help them determine how to manage the pill’s interactions with other drugs, with an eye toward helping prescribers find ways to get the medication to more patients.
Continue to STAT+ to read the full story…
